{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:46:14Z","timestamp":1791359174742,"version":"4.3.1"},"reference-count":24,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Colony stimulating factors (CSF) are widely prescribed to avoid febrile neutropenia (FN) among cancer patients receiving chemotherapy, but studies show their use is often not consistent with practice guidelines. In addition, there is limited high quality evidence assessing benefits and harms of primary prophylactic-CSF (PP-CSF) in the setting of chemotherapy that poses an intermediate risk of FN. To address these issues, with funding from the Patient Centered Outcomes Research Institute (PCORI) and the National Cancer Institute's Community Oncology Research Program, SWOG is sponsoring a prospective, cluster randomized controlled pragmatic trial of an automated order entry protocol for PP-CSF among patients with breast, lung and colorectal cancer receiving myelosuppressive chemotherapy, with a nested randomized controlled trial of PP-CSF for patients receiving intermediate risk chemotherapy. Primary outcomes include adherence to practice guidelines, overall rates of FN and rates of FN among persons receiving intermediate risk chemotherapy. The study, the first pragmatic trial in the National Cancer Institute's cancer cooperative clinical trials network, will provide critical evidence to inform physician and patient decision-making around PP-CSF use and practice policies regarding automated orders in cancer components.<\/jats:p>","DOI":"10.2217\/cer-2017-0005","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T13:11:30Z","timestamp":1499433090000},"page":"461-470","source":"Crossref","is-referenced-by-count":14,"title":["A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study"],"prefix":"10.57264","volume":"6","author":[{"given":"Aasthaa","family":"Bansal","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"University of Washington School of Pharmacy, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"University of Washington School of Pharmacy, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L","family":"Hershman","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H","family":"Lyman","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"University of Washington School of Pharmacy, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E","family":"Barlow","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"Cancer Research and Biostatistics, Seattle, WA 98101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine S","family":"McCune","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"University of Washington School of Pharmacy, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel RL","year":"2016","unstructured":"Siegel RL , Miller KD , Jemal A . Cancer statistics, 2016 . CA Cancer J. Clin. 66 ( 1 ), 7 \u2013 30 ( 2016 ).","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer NM","year":"2006","unstructured":"Kuderer NM , Dale DC , Crawford J , Cosler LE , Lyman GH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 106 ( 10 ), 2258 \u2013 2266 ( 2006 ).","journal-title":"Cancer"},{"issue":"28","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith TJ","year":"2015","unstructured":"Smith TJ , Bohlke K , Lyman GH Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update . J. Clin. Oncol. 33 ( 28 ), 3199 \u2013 3212 ( 2015 ).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_6_2","unstructured":"National Comprehensive Cancer Network\n                                                . \n                                                Clinical Practice Guidelines in Oncology: Myeloid Growth Factors\n                                                 (\n                                                2016\n                                                ). \n                                                www.nccn.org\/professionals\/physician_gls\/PDF\/myeloid_growth.pdf\n                                                ."},{"issue":"1","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro MS","year":"2011","unstructured":"Aapro MS , Bohlius J , Cameron DA 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours . Eur. J. Cancer 47 ( 1 ), 8 \u2013 32 ( 2011 ).","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/djr152","article-title":"Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes","volume":"103","author":"Potosky AL","year":"2011","unstructured":"Potosky AL , Malin JL , Kim B Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes . J. Natl Cancer Inst. 103 ( 12 ), 979 \u2013 982 ( 2011 ).","journal-title":"J. Natl Cancer Inst."},{"issue":"9","key":"e_1_3_4_9_2","first-page":"678","article-title":"Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer","volume":"16","author":"Ramsey SD","year":"2010","unstructured":"Ramsey SD , Mccune JS , Blough DK Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer . Am. J. Manag. Care 16 ( 9 ), 678 \u2013 686 ( 2010 ).","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford J","year":"2008","unstructured":"Crawford J , Dale DC , Kuderer NM Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice . J. Natl Compr. Canc. Netw. 6 ( 2 ), 109 \u2013 118 ( 2008 ).","journal-title":"J. Natl Compr. Canc. Netw."},{"issue":"14","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","article-title":"American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology","volume":"30","author":"Schnipper LE","year":"2012","unstructured":"Schnipper LE , Smith TJ , Raghavan D American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology . J. Clin. Oncol. 30 ( 14 ), 1715 \u2013 1724 ( 2012 ).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_12_2","unstructured":"National Comprehensive Cancer Network\n                                                . \n                                                Clinical Practice Guidelines in Oncology: Breast Cancer\n                                                 (\n                                                2016\n                                                ). \n                                                www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf\n                                                ."},{"key":"e_1_3_4_13_2","unstructured":"National Comprehensive Cancer Network\n                                                . \n                                                Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer\n                                                 (\n                                                2016\n                                                ). \n                                                www.nccn.org\/professionals\/physician_gls\/PDF\/nscl.pdf\n                                                ."},{"issue":"3","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford J","year":"1991","unstructured":"Crawford J , Ozer H , Stoller R Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N. Eng. J. Med. 325 ( 3 ), 164 \u2013 170 ( 1991 ).","journal-title":"N. Eng. J. Med."},{"issue":"6","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial","volume":"80","author":"Pettengell R","year":"1992","unstructured":"Pettengell R , Gurney H , Radford JA Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial . Blood 80 ( 6 ), 1430 \u2013 1436 ( 1992 ).","journal-title":"Blood"},{"key":"e_1_3_4_16_2","unstructured":"Patient-Centered Outcomes Research Institute\n                                                . \n                                                Funding Announcement: Improving Methods for Conducting Patient-Centered Outcomes Research\n                                                 (\n                                                2014\n                                                ). \n                                                www.pcori.org\/sites\/default\/files\/PCORI-PFA-2014-Spring-PFA-Improving-Methods.pdf\n                                                ."},{"key":"e_1_3_4_17_2","unstructured":"NCORP: NCI Community Oncology Research Program\n                                                . \n                                                https:\/\/ncorp.cancer.gov\/\n                                                ."},{"key":"e_1_3_4_18_2","unstructured":"National Cancer Institute Community Oncology Research Program\n                                                . \n                                                Research Areas\n                                                 (\n                                                2016\n                                                ). \n                                                https:\/\/ncorp.cancer.gov\/research\/\n                                                ."},{"issue":"21","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer NM","year":"2007","unstructured":"Kuderer NM , Dale DC , Crawford J , Lyman GH . Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review . J. Clin. Oncol. 25 ( 21 ), 3158 \u2013 3167 ( 2007 ).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/PHAR.1008","article-title":"Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy","volume":"32","author":"Mccune JS","year":"2012","unstructured":"Mccune JS , Sullivan SD , Blough DK Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy . Pharmacotherapy 32 ( 1 ), 7 \u2013 19 ( 2012 ).","journal-title":"Pharmacotherapy"},{"issue":"4","key":"e_1_3_4_21_2","first-page":"337","article-title":"Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134-week chemotherapy regimens in community oncology practices","volume":"13","author":"Morrison VA","year":"2007","unstructured":"Morrison VA , Wong M , Hershman D , Campos LT , Ding B , Malin J . Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134-week chemotherapy regimens in community oncology practices . J. Manag. Care Pharm. 13 ( 4 ), 337 \u2013 348 ( 2007 ).","journal-title":"J. Manag. Care Pharm."},{"issue":"12","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/jnci\/djr195","article-title":"Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy","volume":"103","author":"Kuderer NM","year":"2011","unstructured":"Kuderer NM , Lyman GH . Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy . J. Natl Cancer Inst. 103 ( 12 ), 910 \u2013 913 ( 2011 ).","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3816\/CBC.2005.n.029","article-title":"Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients","volume":"6","author":"Smith K","year":"2005","unstructured":"Smith K , Wray L , Klein-Cabral M Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients . Clin. Breast Cancer 6 ( 3 ), 260 \u2013 266 ( 2005 ).","journal-title":"Clin. Breast Cancer"},{"issue":"9","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy","volume":"117","author":"Lyman GH","year":"2011","unstructured":"Lyman GH , Kuderer NM , Crawford J Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy . Cancer 117 ( 9 ), 1917 \u2013 1927 ( 2011 ).","journal-title":"Cancer"},{"issue":"3","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10549-012-2400-2","article-title":"Supplement use during an intergroup clinical trial for breast cancer (S0221)","volume":"137","author":"Zirpoli GR","year":"2013","unstructured":"Zirpoli GR , Brennan PM , Hong CC Supplement use during an intergroup clinical trial for breast cancer (S0221) . Breast Cancer Res. Treat. 137 ( 3 ), 903 \u2013 913 ( 2013 ).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O'Brien PC","year":"1979","unstructured":"O'Brien PC , Fleming TR . A multiple testing procedure for clinical trials . Biometrics 35 ( 3 ), 549 \u2013 556 ( 1979 ).","journal-title":"Biometrics"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:41:15Z","timestamp":1679229675000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.2217\/cer-2017-0005"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0005","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}